Penumbra (PEN) is a strong "strategic and financial" fit for Boston Scientific (BSX) and the pending merger is expected to support Boston Scientific's growth profile, RBC Capital Markets said.

The company's Q4 beat was driven by notable outperformance in embolization and access segments. Total revenue came in at about $385 million, up roughly 21% year on year. Adjusted EPS came in at $1.18, beating the consensus of $1.11, the brokerage said in a Wednesday note.

The investment firm expects 2026 adjusted EPS of $5.19 and revenue of $1.61 billion.

RBC noted that Penumbra has a large addressable patient population for intervention and immersive health and it will continue to be a leader in the neurovascular segment.

The brokerage has a sector perform rating on the stock, with a $374 price target.

Price: 339.99, Change: +1.32, Percent Change: +0.39